Board Meeting
Vineet Laboratories Board Meeting on 2026-10-26
Vineet Laboratories Ltd: Board meeting on 2026-10-26 to consider and approve unaudited standalone financial results for quarter ended 2026-06-30 and Limited Review Report.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
1
Neutral
6
Bullish
7
Bearish
13
Neutral
6
Bullish
27
Bearish
12
Neutral
0
Bullish
20
Bearish
1
Neutral
6
Bullish
7
Bearish
1
Neutral
6
Bullish
7
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Upcoming Result Date: Oct 25, 2026
Pharmaceuticals & Biotechnology
Pharmaceuticals
68 Cr
Low Risk
61.5
34.8
-0.6
1.5
43.56
28.00
Sales CAGR
Profit CAGR
ROE
ROCE

Vineet Laboratories Ltd (VINEETLAB) is currently trading at 37.72 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vineet Laboratories Limited specializes in the manufacture of drug intermediates and bulk drugs, vital components for active pharmaceutical ingredients (APIs). Its state-of-the-art facility boasts a versatile setup with stainless steel and glass-lined reactors, suited for varying batch sizes and specialized in handling pyrophoric chemicals like n-Butyl Lithium. The company focuses on exporting API intermediates, fine chemicals, and custom synthesis molecules, collaborating with exporters globally. Originally Ortin Laboratories, the company underwent a demerger in 2020, strengthening its focus on pharmaceutical intermediates and fine chemicals. Vineet Laboratories is a preferred partner for renowned companies such as Gilead Sciences and Cipla, highlighting its strong capabilities in product development and process technology.
Over the past 52 weeks, Vineet Laboratories Ltd has traded between a low of ₹28.00 and a high of ₹43.56. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vineet Laboratories Ltd has a market capitalization of approximately 68.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vineet Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 68.28 Cr, Vineet Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vineet Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vineet Laboratories Ltd is 61.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Board Meeting
Vineet Laboratories Ltd: Board meeting on 2026-10-26 to consider and approve unaudited standalone financial results for quarter ended 2026-06-30 and Limited Review Report.
Regulatory/Compliance Filing
Vineet Laboratories filed a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 2026-09-30, certifying dematerialisation procedures and that no securities were received for demat/remat during the quarter.